IVVD
Invivyd, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.55
−7.94%Oct 21, 2026, 11:01 UTC
Invivyd presented preclinical data on VMS063, an investigational monoclonal antibody candidate for measles, at IDWeek 2026.
Source:Oct 14, 2026, 11:01 UTC
Invivyd and the SPEAR Study Group announced the initiation of the FLINTLOCK Phase 2 clinical trial evaluating VYD2311 in individuals with Long COVID or Post-Vaccination Syndrome.
Source:Oct 5, 2026, 11:01 UTC
Invivyd, Inc. granted six newly hired non-executive employees options to purchase an aggregate of 157,500 shares of its common stock on October 1, 2026, under its 2026 Inducement Plan and Nasdaq Listing Rule 5635(c)(4).
Source:Sep 29, 2026, 11:01 UTC
Invivyd, Inc. announced positive topline results from its LIBERTY Phase 3 study showing VYD2311 was safer and better tolerated than mRNA-based COVID-19 vaccine COMIRNATY, and announced plans for regulatory submission of VYD2311.
Sep 1, 2026, 11:27 UTC
Invivyd, Inc. appointed Ajay Royan as Lead Independent Director, effective August 30, 2026.
Sep 1, 2026, 11:27 UTC
Invivyd, Inc. appointed Marc Elia as Chief Executive Officer and Chairman of the Board, effective August 30, 2026.
Aug 13, 2026, 20:05 UTC
Invivyd, Inc. announced its financial results for the second quarter ended June 30, 2026, and recent business highlights.
Source:Aug 4, 2026, 11:01 UTC
Invivyd granted options to purchase 277,500 shares of common stock to ten newly hired non-executive employees as an inducement for employment.
Source:Jul 6, 2026, 11:01 UTC
The U.S. FDA sent Invivyd a Notice of Termination for the Emergency Use Authorization of PEMGARDA, effective June 29, 2027.
Source:Jun 9, 2026, 11:01 UTC
Invivyd dosed first participants in its LIBERTY Phase 3 clinical trial evaluating VYD2311 antibody versus mRNA COVID vaccine and co-administration.